Page 6 - Natco Pharma

Natco plans to double drug filings next year

The company aims to file six abbreviated new drug applications (ANDA) during current financial year

Maylan gets favourable ruling on one more patent of Copaxone

The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles

Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents

In August 2014, Mylan had filed the abbreviated new drug application for multiple sclerosis drug Copaxone 40 mg/ml with the US FDA

Natco Pharma zooms on EIR for Chennai facility

The stock moved higher to its fresh lifetime high of Rs 703, up 7% on the National Stock Exchange.

Natco gets EIR from USFDA for Kothur facility

Company's shares were trading 1.10% higher at Rs 641 on BSE in afternoon session

Natco Pharma Q1 net profit jumps almost 70% to Rs 48 crore

Formulations' share in total income of the company rose to 87% in the quarter, compared to 76.49% in the corresponding quarter last fiscal.

Natco Pharma Q1 net up 69.7 pc to Rs 47.65 crore

Shares of Natco Pharma ended 1.65 per cent down at Rs 625.80 on BSE

Natco Pharma gets final approval for Tamiflu capsules in the US

The company filed ANDA, containing a para IV certification, claiming first to file status in 2011 and was granted tentative approval by USFDA in March 2014

Natco Pharma shares soar over 7% on nod for Tamiflu drugs

At NSE, it moved up by 6.89 per cent to touch its 52-week high of Rs 650

Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu

The stock rallied 7% to Rs 650 also its 52-week high on the National Stock Exchange in early morning trade.

Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets

The stock was trading higher by 4% to Rs 552, extending its Wednesday's 6% rally on the BSE

Natco Pharma gains on tentative nod from USFDA for cancer drug

The stock up 9% to Rs 523 after the company said that its marketing partner, Mylan Inc., has received a US regulator tentative nod Sorafenib, the generic version of Nexavar.

Natco Pharma gains on sale of non-core business in US

The board approved the sale of Save Mart Pharmacy Stores located in USA which is non-core business

US regulator looms over Natco prospects

Company says no impact on product pipeline but Street awaits more clarity

Natco Pharma slips on USFDA observations

The stock slipped 11% to Rs 417 on the BSE in early morning trade.

USFDA observations on 2 units not to impact products: Natco

Natco Pharma Ltd has already sent response and compliance report for these observations